Are Maternal Mental Health Digital Therapeutics Ready for Prime Time?
To date, U.S. adoption of DTX has been slow due to limited...
Topic: Treatment
One Year Later: How Insurers Are Covering Zurzuvae, the First Postpartum Depression Pill
It’s been a year since Zurzuvae™, the first oral postpartum depression drug...
New Psychedelic for Postpartum Depression Now Being Studied
In 2024, Reunion Neuroscience announced the launch of phase 2 of the...
The First Digital Therapeutic for Maternal Mental Health is Approved by the FDA
Curio’s MamaLift Plus™ is an eight-week prescription digital therapeutic that provides symptomatic...
Zurzuvae, the New Postpartum Depression Drug Now Available in the U.S. – This is How Insurers Have Responded
Zurzuvae™, the new first-of-its-kind 14-day postpartum depression pill, recently available in the...
The Cost of ZURZUVAE™ – After Insurance Coverage
On November 7, 2023, Sage Therapeutics announced the wholesale cost of ZURZUVAE™,...
FDA Approves Zuranolone, a Pill for Postpartum Depression Treatment
August 4, 2023, marked a significant milestone in the field of maternal...
1-7 of 7 Results
Load More Articles